Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Common Equity: 2020-2023

Historic Common Equity for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to $90.6 million.

  • Immuneering's Common Equity fell 44.51% to $57.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $57.7 million, marking a year-over-year decrease of 44.51%. This contributed to the annual value of $90.6 million for FY2023, which is 17.55% down from last year.
  • Immuneering's Common Equity amounted to $90.6 million in FY2023, which was down 17.55% from $109.9 million recorded in FY2022.
  • In the past 5 years, Immuneering's Common Equity ranged from a high of $156.0 million in FY2021 and a low of -$22.5 million during FY2020.
  • Over the past 3 years, Immuneering's median Common Equity value was $109.9 million (recorded in 2022), while the average stood at $118.8 million.
  • In the last 5 years, Immuneering's Common Equity soared by 793.82% in 2021 and then declined by 29.57% in 2022.
  • Immuneering's Common Equity (Yearly) stood at -$22.5 million in 2020, then spiked by 793.82% to $156.0 million in 2021, then dropped by 29.57% to $109.9 million in 2022, then decreased by 17.55% to $90.6 million in 2023.